Lyophilized powder: -20C for routine use, -80C for archival
Researchers documented these milestones in uncovering the vision risks: Summer 2023: Three NAION cases presented at Mass Eye and Ear within a short period, all involving semaglutide users July 2024: Publication of the landmark Harvard study in JAMA Ophthalmology revealing increased NAION risk December 2024: Danish researchers published supporting studies involving over 424,000 patients 2025: Multiple international studies confirmed the association between semaglutide and vision problems The pivotal Harvard study analyzed medical records from 16,827 patients treated between 2017 and 2023, comparing those prescribed semaglutide against patients using other diabetes or weight loss medications
Key Challenges Clinicians Should Prepare For Although more affordable GLP-1 therapies could improve access, several concerns remain
The 50 mg tablet is taken once daily, preferably in the morning, after waking up
515,516,517 GLP-1 may improve the livers antioxidant capacity and metabolic function by activating Sirt1, thereby helping to alleviate the pathological changes associated with NASH